Climb Bio, Inc.

CLYM

Climb Bio, Inc.

CLYM

Insider Sentiment (TTM):

Last Purchase:2026-01-05Last Sale:2026-06-29Shares Purchased (TTM):108,573Shares Sold (TTM):57,215

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:30,336,887Shares Outstanding:68,207,313Institutional Ownership Pct.:44.48%

Earnings Market Reaction:

Filing Date:2026-08-06Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	44	8	36	26	23	29	87	146	223	105	93	57
Marketable Securities Current	139	101	65	61	62	69	64	47	0	0	14	50
Prepaid Expense And Other Assets Current	4	4	5	4	3	2	4	4	3	4	3	5
Assets Current	187	113	106	91	87	100	155	198	226	109	110	112
Marketable Securities Noncurrent	56	37	60	89	103	100	62	25	-	-	0	-
Operating Lease Right Of Use Asset	1	0	1	1	1	0	0	0	0	0	0	0
Property Plant And Equipment Net	1	0	0	0	0	-	0	-	-	-	-	-
Other Assets Noncurrent	2	2	2	2	1	0	0	0	0	0	0	0
Assets	246	152	168	182	192	201	217	222	226	109	110	113
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	1	2	0	1	1	1	0	1	0	0	1
Accrued Liabilities And Other Liabilities	4	3	4	4	5	6	4	3	3	3	2	2
Operating Lease Liability Current	1	0	0	0	0	0	0	0	0	0	0	0
Liabilities Current	6	4	7	5	6	7	5	3	4	3	3	3
Other Liabilities Noncurrent	-	-	-	-	-	-	0	0	0	0	0	0
Operating Lease Liability Noncurrent	1	0	0	0	0	0	0	0	0	0	0	0
Liabilities	7	4	7	5	7	7	5	3	4	3	3	3
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital Common Stock	557	451	450	449	445	444	442	440	435	264	264	262
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	0	0	0	0	0	0	0	-0	-0
Retained Earnings Accumulated Deficit	-317	-303	-290	-272	-259	-251	-230	-221	-213	-158	-156	-152
Stockholders Equity	240	148	160	177	186	193	212	219	222	106	108	110
Liabilities And Stockholders Equity	246	152	168	182	192	201	217	222	226	109	110	113
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	250	250	250	250	250	250	250	250	250	250	250	250
Common Stock Shares Issued	57	48	48	68	68	68	67	67	67	28	28	27
Shares Outstanding	57	48	48	68	68	68	67	67	67	28	28	27
Income Tax Expense Benefit	-	-	-	-	-	-	-	0	-	-	-	0

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-7.98%	9.82%	7.81%	-	-	-	-	-	-	-	-	-
2025	18.80%	9.40%	23.93%	48.45%	22.98%	27.33%	-3.08%	152.82%	157.44%	-5.01%	23.68%	48.85%
2024	11.14%	-17.02%	-1.25%	22.96%	-14.14%	-36.44%	-20.53%	-40.79%	-50.00%	-3.08%	-0.77%	-3.08%
2023	-	-	-	-2.21%	-2.95%	-4.06%	3.16%	14.23%	4.74%	40.51%	201.09%	221.53%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30
Liquidity Ratios
Current Ratio	31.45	27.86	15.16	18.38	14.08	14.25	31.41	57.73	60.41	37.02	38.92	38.76
Quick Ratio	30.86	26.91	14.47	17.56	13.65	13.94	30.61	56.49	59.65	35.60	37.70	37.03
Working Capital	180.70M	109.33M	98.87M	86.02M	81.18M	93.24M	149.94M	194.19M	222.26M	106.27M	107.42M	109.53M
Leverage & Debt
Debt to Equity	0.03	0.03	0.05	0.03	0.04	0.04	0.03	0.02	0.02	0.03	0.03	0.03
Debt Ratio	0.03	0.03	0.04	0.03	0.03	0.04	0.02	0.02	0.02	0.03	0.03	0.03
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.76	-0.77	-0.88	-0.75	-0.69	-1.38	-1.53	-1.03	-2.12	-0.53	-1.30	-1.45
Free Cash Flow Per Share TTM	-0.71	-0.78	-0.80	-0.43	-0.36	-0.50	-0.42	-0.23	-0.15	-0.26	-0.76	-1.04
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	23.24%	-43.22%	-19.01%	-26.58%	-27.16%	540.10%	110.42%	76.15%	42.80%	-73.26%	-22.38%	-42.05%
EPS Growth (1Y)	9.37%	-43.84%	-42.48%	-27.65%	-67.29%	162.24%	17.90%	-28.84%	26.29%	-74.37%	-24.32%	-43.62%
Valuation Metrics
P/E TTM	-17.23	-8.85	-4.53	-2.69	-1.79	-0.89	-1.17	-4.93	-3.36	-5.21	-2.07	-1.81
P/B TTM	4.15	3.16	1.69	0.77	0.45	0.43	0.41	1.56	0.97	0.71	0.68	0.65
Market Cap	993.05M	467.22M	271.25M	136.69M	83.81M	82.30M	86.69M	341.10M	215.79M	75.73M	72.87M	71.20M
Enterprise Value	948.80M	458.86M	235.56M	110.88M	61.12M	53.28M	-535.06K	194.93M	-7.35M	-29.30M	-20.25M	13.84M
Calculated Values
Free Cash Flow TTM	-53.86M	-53.49M	-54.54M	-28.99M	-24.30M	-33.82M	-20.21M	-15.63M	-4.59M	-7.24M	-20.60M	-28.10M
Net Debt	-44.25M	-8.36M	-35.69M	-25.80M	-22.68M	-29.02M	-87.23M	-146.18M	-223.14M	-105.03M	-93.11M	-57.35M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-29Sale

Owner: Brennan, Aoife

Title: President and CEO

Shares: 30,902

Price/Share: $13.17

Value: $406,979.34

Shares Owned: 87,731

Relationship: Director,Officer

Ownership: Direct

2026-02-26Sale

Owner: Thomas, Stephen Basil

Title: -

Shares: 16,313

Price/Share: $7.01

Value: $114,354.13

Shares Owned: 154,657

Relationship: Director

Ownership: Direct

2026-02-13Sale

Owner: Thomas, Stephen Basil

Title: -

Shares: 10,000

Price/Share: $5.81

Value: $58,100.00

Shares Owned: 204,657

Relationship: Director

Ownership: Direct

2026-01-05Purchase

Owner: Ra, Capital Healthcare Fu…

Title: -

Shares: 7,111

Price/Share: $3.50

Value: $24,888.50

Shares Owned: 3,403,429

Relationship: Director,TenPercentOwner

Ownership: Indirect

2025-12-12Purchase

Owner: Kolchinsky, Peter, Shah R…

Title: -

Shares: 101,462

Price/Share: $2.86

Value: $290,181.32

Shares Owned: 3,396,318

Relationship: Director

Ownership: Indirect

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-29	Brennan, Aoife	Director,Officer	President and CEO	Direct	Sale	30,902	13.17	$406,979.34	87,731	4
2026-02-26	Thomas, Stephen Basil	Director	-	Direct	Sale	16,313	7.01	$114,354.13	154,657	4
2026-02-13	Thomas, Stephen Basil	Director	-	Direct	Sale	10,000	5.81	$58,100.00	204,657	4
2026-01-05	Ra, Capital Healthcare Fu…	Director,TenPercentOwner	-	Indirect	Purchase	7,111	3.50	$24,888.50	3,403,429	4
2025-12-12	Kolchinsky, Peter, Shah R…	Director	-	Indirect	Purchase	101,462	2.86	$290,181.32	3,396,318	4
2025-06-30	Brennan, Aoife	Director,Officer	President and CEO	Direct	Sale	20,618	1.22	$25,153.96	48,132	4
2025-06-20	Pimblett, Emily	Officer	SVP, Finance & CAO	Direct	Sale	1,242	1.24	$1,540.08	18,888	4
2025-03-20	Pimblett, Emily	Officer	SVP, Finance & CAO	Direct	Sale	1,199	1.31	$1,570.69	15,130	4
2024-12-19	Pimblett, Emily	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	1,235	2.02	$2,494.70	11,329	4
2024-09-20	Pimblett, Emily	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	1,191	8.12	$9,670.92	7,564	4
2024-07-22	Morisset, Valerie	Officer	EVP, R&D AND CSO	Direct	Sale	69,005	8.02	$553,420.10	31,317	4
2024-07-18	Morisset, Valerie	Officer	EVP, R&D AND CSO	Direct	Sale	38,576	6.93	$267,331.68	160,523	4
2024-07-16	Morisset, Valerie	Officer	EVP, R&D AND CSO	Direct	Sale	50,000	7.13	$356,500.00	202,306	4
2024-07-15	Morisset, Valerie	Officer	EVP, R&D AND CSO	Direct	Sale	42,377	7.01	$297,062.77	252,306	4
2024-07-11	Morisset, Valerie	Officer	EVP, R&D AND CSO	Direct	Sale	50,000	7.11	$355,500.00	344,683	4
2024-07-05	Morisset, Valerie	Officer	EVP, R&D AND CSO	Direct	Sale	12,342	7.06	$87,134.52	450,614	4
2024-07-03	Morisset, Valerie	Officer	EVP, R&D AND CSO	Direct	Sale	50,000	6.76	$338,000.00	462,956	4
2024-06-27	Kolchinsky, Peter, Ra Cap…	Director,TenPercentOwner	-	Indirect	Purchase	13,008,546	3.84	$49,952,816.64	23,521,757	4
2024-06-20	Pimblett, Emily	Officer	CHIEF ACCOUNTING OFFICER	Direct	Sale	1,245	7.21	$8,976.45	3,755	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

44.48%

Inst. Shares: 30,336,887

Shares Outstanding: 68,207,313

2025-12-31

43.16%

Inst. Shares: 29,266,982

Shares Outstanding: 67,812,145

2025-09-30

64.78%

Inst. Shares: 44,049,717

Shares Outstanding: 68,003,248

2025-06-30

72.92%

Inst. Shares: 49,282,963

Shares Outstanding: 67,585,121

2025-03-31

75.99%

Inst. Shares: 51,265,248

Shares Outstanding: 67,462,450

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	30,336,887	68,207,313	44.48%
2025-12-31	29,266,982	67,812,145	43.16%
2025-09-30	44,049,717	68,003,248	64.78%
2025-06-30	49,282,963	67,585,121	72.92%
2025-03-31	51,265,248	67,462,450	75.99%
2024-12-31	54,976,799	48,163,301	114.15%
2024-09-30	53,930,942	67,014,183	80.48%
2024-06-30	49,893,986	30,349,562	164.40%
2024-03-31	16,815,315	27,638,528	60.84%
2023-12-31	16,813,642	26,987,122	62.30%
2023-09-30	16,698,191	27,071,053	61.68%
2023-06-30	16,700,655	26,840,555	62.22%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Climb Bio, Inc. (CLYM) — SEC Financial Statements & Analysis

Climb Bio, Inc. (CLYM) is a pharmaceutical preparations company, incorporated in DE. Climb Bio, Inc. trades on Nasdaq as: CLYM. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), Climb Bio, Inc. reported a Debt-to-Equity ratio of 0.03x, a Price-to-Book (P/B) ratio of 4.15x (TTM), at a market cap of $993.05M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.03x
P/B TTM: 4.15x
Market Cap: $993.05M

Data as of 2026-06-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Climb Bio, Inc. in?

Climb Bio, Inc. (CLYM) operates in the Pharmaceutical Preparations industry.

What is CLYM's market cap?

Climb Bio, Inc. (CLYM) has a market capitalization of $993.05M as of 2026-06-30.

What exchange does CLYM trade on?

Climb Bio, Inc. (CLYM) trades on the Nasdaq.

Where is Climb Bio, Inc. incorporated?

Climb Bio, Inc. is incorporated in DE.

Climb Bio, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Climb Bio, Inc. (CLYM) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Climb Bio, Inc. (CLYM) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.